Company Filing History:
Years Active: 2009
Title: Stephanie Broome: Innovator in Autoimmune Disease Treatment
Introduction
Stephanie Broome is a notable inventor based in Palo Alto, California. She has made significant contributions to the field of autoimmune disease treatment, particularly through her innovative research and patent.
Latest Patents
Stephanie holds a patent for the "Treatment of demyelinating autoimmune disease with modified ordered peptides." This patent describes compositions and methods for the treatment or prevention of autoimmune diseases. The therapeutic doses of modified ordered peptides comprise amino acids representing a consensus sequence of proteins identified as targets of the autoimmune T and B cell response. Notably, the patent focuses on therapeutic ordered peptides related to autoantigens in multiple sclerosis, including myelin proteins such as MBP, MOG, PLP, MAG, and cyclic nucleotide phosphodiesterase. The therapeutic peptides can be administered through various methods, including topical, parenteral, or transdermal routes. The compositions may also include other therapeutically active agents.
Career Highlights
Stephanie is currently associated with Bayhill Therapeutics, Inc., where she continues her research and development efforts in the field of autoimmune diseases. Her work has the potential to significantly impact the treatment landscape for conditions like multiple sclerosis.
Collaborations
Stephanie collaborates with Hideki Garren, contributing to the advancement of therapeutic strategies in autoimmune disease treatment.
Conclusion
Stephanie Broome's innovative work in the treatment of autoimmune diseases showcases her dedication to improving patient outcomes through scientific research and development. Her contributions are paving the way for new therapeutic options in the medical field.